edaravone has been researched along with Brain Edema in 28 studies
Brain Edema: Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone is widely used for treating ischemic stroke, but it is not still confirmed in intracerebral hemorrhage (ICH) as an ideal medication targeting the brain parenchyma." | 7.83 | Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat. ( Gao, M; Ge, GZ; Ji, XC; Sun, YL; Wang, QQ; Xu, RX; Yang, Y; Zhang, GZ; Zhang, HT; Zhang, Y, 2016) |
| "To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms." | 7.81 | [Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015) |
| "In present study, we evaluated acute neuroprotective effects of combined therapy with pharmacologically induced hypothermia and edaravone in a rat model of intracerebral hemorrhage (ICH)." | 7.81 | Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage. ( Liu, C; Sun, Z; Zhu, Y, 2015) |
| " In the first, the dose-dependent effects of edaravone on ICH-induced brain injury were examined by measuring brain edema and neurologic deficits." | 7.74 | Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. ( Itano, T; Keep, RF; Kuroda, Y; Miyamoto, O; Nagao, S; Nakamura, T; Tamiya, T; Xi, G; Yamashita, S; Zhang, X, 2008) |
| "We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil." | 7.71 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002) |
| "Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls." | 5.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "Edaravone is widely used for treating ischemic stroke, but it is not still confirmed in intracerebral hemorrhage (ICH) as an ideal medication targeting the brain parenchyma." | 3.83 | Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat. ( Gao, M; Ge, GZ; Ji, XC; Sun, YL; Wang, QQ; Xu, RX; Yang, Y; Zhang, GZ; Zhang, HT; Zhang, Y, 2016) |
| " Previous studies have demonstrated that the free radical scavenger edaravone may prevent neuronal injury and brain edema after ICH." | 3.81 | The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage. ( Cui, D; Liang, S; Shang, H; Yang, D; Zhang, W; Zhao, W, 2015) |
| "To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms." | 3.81 | [Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015) |
| "In present study, we evaluated acute neuroprotective effects of combined therapy with pharmacologically induced hypothermia and edaravone in a rat model of intracerebral hemorrhage (ICH)." | 3.81 | Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage. ( Liu, C; Sun, Z; Zhu, Y, 2015) |
| "Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, reduces brain edema in patients with acute ischemic stroke." | 3.74 | Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. ( Imaizumi, T; Ishikawa, A; Matsumiya, T; Metoki, N; Satoh, K; Taima, K; Toki, T; Yamashita, K; Yoshida, H, 2007) |
| " In the first, the dose-dependent effects of edaravone on ICH-induced brain injury were examined by measuring brain edema and neurologic deficits." | 3.74 | Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. ( Itano, T; Keep, RF; Kuroda, Y; Miyamoto, O; Nagao, S; Nakamura, T; Tamiya, T; Xi, G; Yamashita, S; Zhang, X, 2008) |
| "We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil." | 3.71 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002) |
| "Edaravone was associated with delayed evolution of infarcts and edema in patients with severe carotid-territorial stroke and decreased mortality during the acute stage." | 2.71 | Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. ( Arihiro, S; Fujii, K; Ibayashi, S; Iida, M; Kamouchi, M; Nakane, H; Okada, Y; Toyoda, K, 2004) |
| "Edaravone was approved in Japan for the treatment of acute brain infarction within 24 h after onset in April, 2001." | 2.41 | [Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent]. ( Tanaka, M, 2002) |
| "Edaravone treatment significantly ameliorated neurological deficits, brain edema, and BBB disruption." | 1.51 | The Role of Oxidative Stress in Microvascular Disturbances after Experimental Subarachnoid Hemorrhage. ( Fumoto, T; Katagai, T; Li, Y; Naraoka, M; Ohkuma, H; Shimamura, N, 2019) |
| "Edaravone was treated twice via tail vein; after MCA occlusion and after reperfusion." | 1.43 | A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model. ( Arai, K; Fujiwara, N; Lee, BJ; Lo, EH; Mandeville, ET; Pham, LD; Som, AT, 2016) |
| "Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls." | 1.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "Edaravone-treated animals showed significantly improved neurological outcome." | 1.33 | Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. ( Amemiya, S; Inaba, T; Kamiya, T; Katayama, Y; Kato, K; Nito, C; Shimazaki, K; Ueda, M, 2005) |
| "Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion." | 1.33 | Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Ling, J | 1 |
| Wang, X | 1 |
| Li, T | 1 |
| Liu, J | 1 |
| Lai, Y | 1 |
| Ji, H | 1 |
| Peng, S | 1 |
| Tian, J | 1 |
| Zhang, Y | 2 |
| Hua, Y | 1 |
| Zhou, L | 1 |
| Yang, W | 1 |
| An, W | 1 |
| Kou, X | 1 |
| Ren, J | 1 |
| Su, H | 1 |
| Chen, R | 1 |
| Zhang, Z | 1 |
| Zou, J | 1 |
| Zhao, Z | 1 |
| Chung, C | 1 |
| Bryant, A | 1 |
| Brown, PD | 1 |
| Fumoto, T | 1 |
| Naraoka, M | 1 |
| Katagai, T | 1 |
| Li, Y | 2 |
| Shimamura, N | 1 |
| Ohkuma, H | 1 |
| Fang, W | 1 |
| Zhang, R | 1 |
| Sha, L | 1 |
| Lv, P | 1 |
| Shang, E | 1 |
| Han, D | 1 |
| Wei, J | 1 |
| Geng, X | 1 |
| Yang, Q | 1 |
| Chen, Z | 2 |
| Zhang, J | 2 |
| Chen, Q | 1 |
| Guo, J | 1 |
| Zhu, G | 1 |
| Feng, H | 1 |
| Shang, H | 1 |
| Cui, D | 1 |
| Yang, D | 1 |
| Liang, S | 1 |
| Zhang, W | 1 |
| Zhao, W | 1 |
| Zhang, S | 1 |
| Hou, S | 1 |
| Chen, H | 1 |
| Zhu, Y | 1 |
| Liu, C | 1 |
| Sun, Z | 1 |
| Yang, Y | 1 |
| Zhang, GZ | 1 |
| Gao, M | 1 |
| Ge, GZ | 1 |
| Wang, QQ | 1 |
| Ji, XC | 1 |
| Sun, YL | 1 |
| Zhang, HT | 1 |
| Xu, RX | 1 |
| Fujiwara, N | 1 |
| Som, AT | 1 |
| Pham, LD | 1 |
| Lee, BJ | 1 |
| Mandeville, ET | 1 |
| Lo, EH | 1 |
| Arai, K | 1 |
| Zhou, F | 1 |
| Chen, G | 1 |
| Kikuchi, K | 1 |
| Tancharoen, S | 1 |
| Matsuda, F | 1 |
| Biswas, KK | 1 |
| Ito, T | 1 |
| Morimoto, Y | 1 |
| Oyama, Y | 1 |
| Takenouchi, K | 1 |
| Miura, N | 1 |
| Arimura, N | 1 |
| Nawa, Y | 1 |
| Meng, X | 1 |
| Shrestha, B | 1 |
| Arimura, S | 1 |
| Iwata, M | 1 |
| Mera, K | 1 |
| Sameshima, H | 1 |
| Ohno, Y | 1 |
| Maenosono, R | 1 |
| Tajima, Y | 1 |
| Uchikado, H | 1 |
| Kuramoto, T | 1 |
| Nakayama, K | 1 |
| Shigemori, M | 1 |
| Yoshida, Y | 1 |
| Hashiguchi, T | 1 |
| Maruyama, I | 1 |
| Kawahara, K | 1 |
| Nakamura, H | 1 |
| Uzura, M | 1 |
| Uchida, K | 1 |
| Nakayama, H | 1 |
| Furuya, Y | 1 |
| Hayashi, T | 1 |
| Sekino, H | 1 |
| Ominato, M | 1 |
| Owada, S | 1 |
| Toyoda, K | 1 |
| Fujii, K | 1 |
| Kamouchi, M | 1 |
| Nakane, H | 1 |
| Arihiro, S | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Iida, M | 1 |
| Yu, GL | 1 |
| Wei, EQ | 1 |
| Zhang, SH | 1 |
| Xu, HM | 1 |
| Chu, LS | 1 |
| Zhang, WP | 1 |
| Zhang, Q | 1 |
| Mei, RH | 1 |
| Zhao, MH | 1 |
| Shinohara, Y | 1 |
| Amemiya, S | 1 |
| Kamiya, T | 1 |
| Nito, C | 1 |
| Inaba, T | 1 |
| Kato, K | 1 |
| Ueda, M | 1 |
| Shimazaki, K | 1 |
| Katayama, Y | 2 |
| Lee, JH | 1 |
| Park, SY | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Suda, S | 1 |
| Igarashi, H | 1 |
| Arai, Y | 1 |
| Andou, J | 1 |
| Chishiki, T | 1 |
| Niyaz, M | 1 |
| Numakawa, T | 1 |
| Matsuki, Y | 1 |
| Kumamaru, E | 1 |
| Adachi, N | 1 |
| Kitazawa, H | 1 |
| Kunugi, H | 1 |
| Kudo, M | 1 |
| Ishikawa, A | 1 |
| Yoshida, H | 1 |
| Metoki, N | 1 |
| Toki, T | 1 |
| Imaizumi, T | 1 |
| Matsumiya, T | 1 |
| Yamashita, K | 1 |
| Taima, K | 1 |
| Satoh, K | 1 |
| Nakamura, T | 1 |
| Kuroda, Y | 1 |
| Yamashita, S | 1 |
| Zhang, X | 1 |
| Miyamoto, O | 1 |
| Tamiya, T | 1 |
| Nagao, S | 1 |
| Xi, G | 1 |
| Keep, RF | 1 |
| Itano, T | 1 |
| Watanabe, T | 3 |
| Egawa, M | 1 |
| Tanaka, M | 1 |
| Jin, YJ | 1 |
| Mima, T | 1 |
| Raicu, V | 1 |
| Park, KC | 1 |
| Shimizu, K | 1 |
| Nishi, H | 2 |
| Sakurai, H | 1 |
| Yuki, S | 1 |
| Ishibashi, A | 1 |
| Oishi, R | 1 |
| Itoh, Y | 1 |
| Nishibori, M | 1 |
| Saeki, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy[NCT00153946] | Phase 4 | 814 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for edaravone and Brain Edema
| Article | Year |
|---|---|
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.
Topics: Adrenal Cortex Hormones; Adult; Antipyrine; Bevacizumab; Brain; Brain Edema; Drug Therapy, Combinati | 2018 |
[Clinical guidelines for stroke].
Topics: Anticoagulants; Antipyrine; Arginine; Aspirin; Brain Edema; Edaravone; Fibrinolytic Agents; Free Rad | 2004 |
[Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent].
Topics: Animals; Antipyrine; Brain Edema; Clinical Trials as Topic; Depression, Chemical; Edaravone; Free Ra | 2002 |
1 trial available for edaravone and Brain Edema
| Article | Year |
|---|---|
Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion.
Topics: Aged; Antipyrine; Atrial Fibrillation; Brain Edema; Carotid Artery Thrombosis; Carotid Artery, Inter | 2004 |
24 other studies available for edaravone and Brain Edema
| Article | Year |
|---|---|
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Fr | 2012 |
Y-2 reduces oxidative stress and inflammation and improves neurological function of collagenase-induced intracerebral hemorrhage rats.
Topics: Animals; Brain Edema; Camphanes; Cerebral Hemorrhage; Collagenases; Disease Models, Animal; Drug Com | 2021 |
The Role of Oxidative Stress in Microvascular Disturbances after Experimental Subarachnoid Hemorrhage.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Brain; Brain Edema; Brain Injuries; Disease Models, Anim | 2019 |
Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain.
Topics: Animals; Antipyrine; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; Blotting, W | 2014 |
Neuroprotective effects of edaravone after intraventricular hemorrhage in rats.
Topics: Animals; Antipyrine; Brain Edema; Cerebral Hemorrhage; Cognition Disorders; Edaravone; Free Radical | 2014 |
The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage.
Topics: Animals; Antipyrine; Behavior, Animal; Body Water; Brain Edema; Cell Death; Edaravone; Fluorodeoxygl | 2015 |
[Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury
in rats and its underlying mechanism].
Topics: Animals; Antipyrine; Brain Edema; Brain Ischemia; Cerebral Infarction; Edaravone; Lactates; Malondia | 2015 |
Early Combined Therapy with Pharmacologically Induced Hypothermia and Edaravone Exerts Neuroprotective Effects in a Rat Model of Intracerebral Hemorrhage.
Topics: Animals; Antipyrine; Apoptosis Regulatory Proteins; Blood-Brain Barrier; Blotting, Western; Brain Ed | 2015 |
Stereotactic Administration of Edaravone Ameliorates Collagenase-Induced Intracerebral Hemorrhage in Rat.
Topics: Animals; Antipyrine; Apoptosis; Blood-Brain Barrier; Brain Edema; Cerebral Hemorrhage; Collagenases; | 2016 |
A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model.
Topics: Animals; Antipyrine; Brain Edema; Cerebral Infarction; Cytokines; Edaravone; Free Radical Scavengers | 2016 |
Edaravone reduces brain oedema and attenuates cell death after intracerebral haemorrhage in mice.
Topics: Animals; Antipyrine; Brain; Brain Edema; Cell Death; Cerebral Hemorrhage; Collagenases; Disease Mode | 2009 |
Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4.
Topics: Animals; Antipyrine; Aquaporin 4; Brain Edema; Brain Ischemia; Disease Models, Animal; Edaravone; Fr | 2009 |
Effects of edaravone on experimental brain injury in view of free radical reaction.
Topics: Animals; Antipyrine; Body Water; Brain; Brain Edema; Brain Injuries; Edaravone; Electron Spin Resona | 2003 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; C | 2005 |
Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats.
Topics: Animals; Antipyrine; Apoptosis; bcl-2-Associated X Protein; Brain Edema; Brain Ischemia; Cerebral Co | 2005 |
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede | 2005 |
Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Edema; Brain Ischemia; Edaravone; Female; Free Radical Sc | 2007 |
MCI-186 prevents brain tissue from neuronal damage in cerebral infarction through the activation of intracellular signaling.
Topics: Animals; Animals, Newborn; Antipyrine; Brain Edema; Butadienes; Cell Death; Cells, Cultured; Cerebra | 2007 |
Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia.
Topics: Antipyrine; Astrocytes; Blood-Brain Barrier; Brain Edema; Cell Nucleus; Cells, Cultured; Cerebral Ar | 2007 |
Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage.
Topics: Acute Disease; Animals; Antipyrine; Basal Ganglia; Brain Edema; Cerebral Cortex; Cerebral Hemorrhage | 2008 |
Effects of an antistroke agent MCl-186 on cerebral arachidonate cascade.
Topics: Animals; Antipyrine; Arachidonic Acid; Brain; Brain Edema; Cerebrovascular Disorders; Chromones; Eda | 1994 |
Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils.
Topics: Animals; Anticoagulants; Antipyrine; Arginine; Body Water; Brain Edema; Brain Ischemia; Cerebral Inf | 2002 |
Effect of MCI-186 on brain edema in rats.
Topics: Animals; Antipyrine; Brain Edema; Dexamethasone; Edaravone; Free Radicals; Lipid Peroxides; Lipoxyge | 1989 |
Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipyrine; Biogenic Monoamines; Brain; Brain Edema; Brain | 1989 |